Ranbaxy Laboratories Ltd today said Nihon Pharmaceutical Industry Ltd, a joint venture between the company and Japan-based Nippon Chemiphar Ltd // , has launched the antibiotic 'Clarithromycin' and anti-fungal 'Terbinafine' tablets in the Japanese market.
Clarithromycin has been launched in strengths of 50mg, 200mg and Terbinafine of 125mg. The products have a market size of around 400 million dollars and 300 million dollars respectively in Japan, for the above dosage forms, Ranbaxy said in a statement.
The products would be marketed and promoted jointly by Nippon Chemiphar and Nihon Pharmaceutical and sold in Japan under the Ranbaxy/Nihon Pharmaceutical Industry Ltd label.
"It is our earnest intention to leverage the advantage of an early entry in the progressive opening up of the generic Pharma market of Japan. We intend to rapidly introduce an array of generic therapies from our global portfolio," Ranbaxy s CEO and Managing Director Malvinder Mohan Singh said.
Ranbaxy had entered the Japanese market in the year 2002 through a strategic alliance with Nippon Chemiphar, a mid sized research pharmaceutical company.
In July 2005, the JV between the two companies had introduced its first co-developed product Vogseal O.2mg and 0.3mg tablets for the treatment of diabetes.
Last year, Ranbaxy had also increased its equity stake in Nihon Pharmaceutical, making it a 50:50 joint venture between the company and Nippon Chemiphar.
Source:PTI News
'"/>Page: 1 Related medicine news :1.
Ranbaxy joins hand with Cipla to co-market ciprofloxacin2.
Ranbaxy gets US FDA approval for Lisinopril 3.
Ranbaxy Labs Entry Into Anti-Acne Market 4.
Ranbaxy trying to make inroads in herbal drugs market5.
Lamivudine Manufactured By Ranbaxy gets the nod from the US FDA6.
Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart7.
Ranbaxy opens Drug discovery centre in Gurgaon 8.
Ranbaxy Laboratories All Set To Export Bird Flu Vaccines9.
SRL Ranbaxy offers quicker bird flu diagnostic test10.
Diagnostic Test Launched by Ranbaxy for En Masse Screening of Bird Flu11.
Ranbaxy Launches Once-a-day Inhaler For Asthma Patients